Portfolio | Inka Health

Focused on Impact

Research Principles

High Impact Engagement

Inka Health actively publishes in top journals and presents at premier conferences, avoiding the obscurity of traditional medical literature. Our approach guarantees a lasting impact and legacy in the field of medical research.

Diversity of Experience

Our team, including medical doctors, epidemiologists, and experts in various fields, stands out for the diversity of our experience and the unique approach we bring to analytics.

Setting Standards

Our focus transcends mere data analysis; we're dedicated to influencing medical decision-making. Our quantitative bias work for external control arms has been referenced by NICE in their RWE Framework.

Advanced Methods

We are constantly working to expand our offerings. Our expert team of professionals is passionate about developing the most advanced technologies on the market.

Experience Expert Statistical Consulting Services

500+ publications across multiple disease areas

Cited by NICE in their RWE guidance

Innovative Methods and consulting solutions

Solutions-focused culture leading to application of novel methods

Actively involved in public engagement with regulatory and scientific community

Selected Work

Multi-country real-world oncology database study

This study found that while the use of new therapies improved survival in advanced non-small cell lung cancer patients from 2011 to 2020, the proportion of patients receiving first-line treatment varied by country.

Transportability Real-World Oncology Outcomes

By adjusting for baseline characteristics, transportability analysis can reliably apply U.S. overall survival estimates for advanced NSCLC to Canadian patients, supporting regulatory decision-making

Transportability of Clinical Trial Outcomes to Real-World Populations

Study protocol to test the feasibility and limitations of transportability of US clinical trial outcomes to global real-world populations.

External control arm using real-world oncology data

Use of RWD external control arm to estimate comparative effectiveness of a new treatment vs. SoC for relapsed SCLC in Canada.

Synthetic Data for External Control Arm Analysis

Protocol for a study to test synthetic data as an external control arm in metastatic lung cancer trials, comparing it to real-world data.

Target Trial Emulation

Emulation of a randomized trial using real-world data to compare FOLFIRINOX vs. gemcitabine plus nab-paclitaxel for advanced pancreatic cancer, providing evidence in the absence of head-to-head trials.

Target Trial Emulation

TTE estimated the effectiveness of adding OFS to hormone therapy in premenopausal HR+ breast cancer, emulating SOFT and TEXT trials to ensure reliable, trial-like estimates from real-world data.

Quantitative Bias Analysis

A review of QBA methods in the context of external control arm analysis, examining their application to ensure robust and accurate comparisons in studies utilizing real-world data as a control.

Group-based Trajectory Modelling for Treatment Adherence

This study used group-based trajectory modeling to assess medication adherence patterns and compared its performance to the proportion of days covered and longitudinal K-means methods.

Areas of Work

01.

Causal Inference in Real World Evidence & Target Trial Emulation

02.

Patient Support Programs & Quality of Life (QoL) Indicators

03.

Novel Risk Prediction Modelling

04.

Real-World Evidence Generation

05.

Network Meta-Analysis & Population-Adjusted Indirect Comparisons (MAIC, STC, ML-NMR)

06.

Bayesian Borrowing & Analysis of Basket Trials

07.

Prognostic Modelling Studies & Biomarker Validation

08.

Surrogate Endpoint Analyses

09.

Diagnostic Performance Evaluation Studies

10.

Health Economics Modelling

View our Capabilities

SELECTED Publications

Mackay EK, Springford A. Evaluating treatments in rare indications warrants a Bayesian approach. Frontiers in Pharmacology. 2023;14.
Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Penrod JR, Sharpe DJ, Yates G, Rafiq S, Johannesen K, Siddiqui MK, Vanderpuye-Orgle J. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. Medical Decision Making. 2023 Jan;43(1):91-109.
Thorlund K, Duffield S, Popat S, Ramagopalan S, Gupta A, Hsu G, Arora P, Subbiah V. Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of Comparative Effectiveness Research. 2023 Dec(0):e230147.
Griesinger F, Ramagopalan S, Cheung WY, Wilke T, Mueller S, Gupta A, O’Sullivan DE, Arora P, Brenner DR, Froelich C, Inskip J. Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real‐world databases. Cancer. 2023 Nov 7.
Boyne DJ, Dawe DE, Shakir H, Joe-Uzuegbu O, Farah E, Pabani A, Baratta C, Brenner DR, Cheung WY. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis. Targeted Oncology. 2023 Sep;18(5):697-705.
Wilkinson, S., Gupta, A., Scheuer, N., Mackay, E., Arora, P., Thorlund, K., Wasiak, R., Ray, J., Ramagopalan, S., & Subbiah, V. “Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-World Data.” JAMA Network Open, vol. 4, no. 10, 2021, https://doi.org/10.1001/jamanetworkopen.2021.26306
Xu Y, Chow R, Chandereng T, Murdy K, Sinha R, Lee-Ying R, Abedin T, Cheung W, Nguyen T, Pham TM, Lee SL. Definitive Chemoradiotherapy vs. Trimodal Therapy for Locally Advanced Esophageal or Junctional Adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2022 Nov 1;114(3):e168-9.
Litt I, Gibson A, Dean M, Elegbede A, Bebb G, Cheung W, Pabani A. EP08. 02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib+/-Radiation Therapy in a Real-World Canadian Cohort. Journal of Thoracic Oncology. 2022 Sep 1;17(9):S434.
Batra A, Ramjeesingh R, Meyers BM, Vickers MM, Goodwin RA, Armstrong DE, Cheung WY, Kim C, Cancer Health Outcomes Research Database (CHORD) Consortium. Treatment patterns and survival outcomes of older patients with advanced pancreatic cancer (APC): A Canadian real-world evidence study.
Batra A, Kong S, Cheung WY. Eligibility of real-world patients with metastatic breast cancer for clinical trials. The Breast. 2020 Dec 1;54:171-8.
Ramagopalan SV, Popat S, Gupta A, Boyne DJ, Lockhart A, Hsu G, O’Sullivan DE, Inskip J, Ray J, Cheung WY, Griesinger F. Transportability of overall survival estimates from US to Canadian patients with advanced non–small cell lung cancer with implications for regulatory and health technology assessment. JAMA Network Open. 2022 Nov 1;5(11):e2239874-.
Alghamdi MA, Amaro CP, Lee‐Ying R, Sim HW, Samwi H, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database. Cancer Medicine. 2020 Jul;9(14):4918-28.
Elegbede AA, Gibson AJ, Fu H, Dean ML, Ezeife DA, Lau H, Cheung WY, Bebb DG. Real-world adherence to guideline-recommended treatment for small cell lung cancer. American journal of clinical oncology. 2020 Apr 17;43(4):236-42.
Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, Penrod JR, Lakhdari K, Lacoin L, Cheung WY. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC cancer. 2022 Dec;22(1):1-2.

Boyne DJ, Dawe DE, Shakir H, Joe-Uzuegbu O, Farah E, Pabani A, Baratta C, Brenner DR, Cheung WY. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis. Targeted Oncology. 2023 Sep;18(5):697-705. 🔗

Wilkinson S, Gupta A, Scheuer N, Mackay E, Arora P, Thorlund K, Wasiak R, Ray J, Ramagopalan S, Subbiah V. Assessment of alectinib vs ceritinib in ALK-positive non–small cell lung cancer in phase 2 trials and in real-world data. JAMA Network Open. 2021 Oct 1;4(10):e2126306-. 🔗

Basmadjian RB, Kong S, Boyne DJ, Jarada TN, Xu Y, Cheung WY, Lupichuk S, Quan ML, Brenner DR. Developing a prediction model for pathologic complete response following neoadjuvant chemotherapy in breast cancer: a comparison of model building approaches. JCO Clinical Cancer Informatics. 2022 Feb;6:e2100055. 🔗

Gupta A, Arora P, Brenner D, Vanderpuye-Orgle J, Boyne DJ, Edmondson-Jones M, Parkhomenko E, Stevens W, Dudani S, Heng DY, Wagner S. Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics. 2021 Mar;5:326-37. 🔗

Boyne DJ, Brenner DR, Sajobi TT, Hilsden RJ, Yusuf D, Xu Y, Friedenreich CM, Cheung WY. Development of a model for predicting early discontinuation of adjuvant chemotherapy in stage III colon cancer. JCO Clinical Cancer Informatics. 2020 Oct;4:972-84. 🔗

Arora P, Boyne D, Slater JJ, Gupta A, Brenner DR, Druzdzel MJ. Bayesian networks for risk prediction using real-world data: a tool for precision medicine. Value in Health. 2019 Apr 1;22(4):439-45. 🔗

Xu Y, Kong S, Cheung WY, Bouchard-Fortier A, Dort JC, Quan H, Buie EM, McKinnon G, Quan ML. Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data. BMC cancer. 2019 Dec;19(1):1-0. 🔗

He J, Berringer H, Heeg B, Ruan H, Kampfenkel T, Dwarakanathan HR, Johnston S, Mendes J, Lam A, Bathija S, Mackay E. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. Advances in Therapy. 2022 Sep;39(9):4230-49.

He J, Berringer H, Heeg B, Kampfenkel T, Dwarakanathan HR, Johnston S, Mendes J, Lam A, Bathija S, Mackay E. Indirect treatment comparisons of daratumumab, pomalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone or bortezomib and dexamethasone in patients with difficult-to-treat relapsed/refractory multiple myeloma. Blood. 2021 Nov 23;138:4083.